Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead candidate, SL-172154, in treating people with advanced ovarian cancer, the company announced in a press release. The trial (NCT04406623) is recruiting up to 33 patients at three sites in the U.S.: the John Wayne Cancer Institute at Providence St. John’s Health Center in California, START Midwest in Michigan, and the Stephenson Cancer Center at Oklahoma University. For more information, click here. SL-172154 is designed to modulate…
You must be logged in to read/download the full post.
The post Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens appeared first on BioNewsFeeds.